Warszawa

• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnorma … Recruiting
  2022-501943-34-00 5 2023-06-27 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic St … Recruiting
  2023-510548-19-00 4 2023-03-02 Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
• SACK Recruiting
  2022-501600-10-00 5 2023-02-07 Atrial fibrillation and Chronic Kidney Disease stage 5
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting
  2023-506239-14-00 5 2022-12-13 Ulcerative Colitis
• Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss Recruiting
  2024-513835-25-00 5 2022-10-27 Agitation with Dementia of the Alzheimer's Type
• A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting
  2023-509045-13-00 5 2022-02-28 Moderately to severely active Crohn's disease (CD)
• Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrom … Recruiting
  2024-515058-26-00 5 2021-12-17 NEPHROTIC SYNDROME
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting
  2023-506131-15-00 5 2019-09-10 Juvenile Idiopathic Arthritis
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended recruitment
  2023-503539-16-00 5 2025-11-11 Non-small Cell Lung Cancer (NSCLC)
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles … Ended recruitment
  2024-518156-24-00 5 2025-11-10 Atopic Dermatitis
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended recruitment
  2024-519370-40-00 5 2025-07-16 Alopecia areata
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT … Ended recruitment
  2024-515523-11-00 5 2025-06-09 Chronic Weight Management
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended recruitment
  2024-515494-95-00 4 2025-05-26 Moderate to Severe Atopic Dermatitis (AD)
• A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat … Ended recruitment
  2024-513348-27-00 5 2025-05-09 Plaque psoriasis
• Study of the Safety and lmmunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, T … Ended recruitment
  2024-512271-13-00 5 2025-05-08 Pneumococcal immunisation
• AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI … Ended recruitment
  2023-505601-16-00 5 2025-04-22 Chronic Migraine
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Ended recruitment
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat … Ended recruitment
  2024-513015-27-00 5 2025-01-09 Moderately to Severely Active Ulcerative Colitis (UC)
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended recruitment
  2024-511881-35-00 5 2024-12-17 Prurigo Nodularis

Showing 73–96 of 186 trials